Advertisement

Diabetes prevention and cardiovascular complications

  • Silvio E. InzucchiEmail author
  • Catherine M. Viscoli
  • Lawrence H. Young
  • Walter N. Kernan
Letter
  • 273 Downloads

To the Editor: The review by Nathan et al recently published in Diabetologia provides an excellent discussion of the relationship between diabetes prevention and microvascular and cardiovascular (CV) complications [1]. We agree that the existing data are quite limited, although somewhat more robust for microvascular disease. This is not unexpected, given that hyperglycaemia is more closely aligned with retinopathy and nephropathy than with atherosclerotic CV disease (ASCVD). We noted one important omission, however, from this otherwise complete review. Insulin Resistance Intervention after Stroke (IRIS) was a large, multi-national clinical trial, funded by the US National Institutes of Health, that randomised insulin-resistant (but non-diabetic) individuals with recent stroke or transient ischaemic attack to receive the thiazolidinedione pioglitazone or placebo and assessed the impact on future CV events as well as the diagnosis of diabetes [2].

Pioglitazone is a potent...

Keywords

Cardiovascular disease Complications Diabetes prevention Impaired fasting glucose Impaired glucose tolerance Pioglitazone Thiazolidinediones 

Abbreviations

ACT NOW

Actos Now for Prevention of Diabetes

ASCVD

Atherosclerotic cardiovascular disease

CV

Cardiovascular

IFG

Impaired fasting glucose

IGT

Impaired glucose tolerance

IRIS

Insulin Resistance Intervention after Stroke

MI

Myocardial infarction

RRR

Relative risk reduction

Notes

Contribution statement

All authors were responsible for drafting the article or revising it critically for important intellectual content, and all authors approved the version to be published.

Duality of interest

SEI has served on clinical trial steering or executive committees for Eisai (through the Thrombolysis in Myocardial Infarction [TIMI] Study Group) and AstraZeneca, which have examined diabetes prevention through weight loss or glucose lowering medications. The other authors declare no dualities of interest associated with their contribution to this manuscript.

References

  1. 1.
    Nathan DM, Bennet PH, Crandall JP et al (2019) Does diabetes prevention translate into reduced long-term vascular complications of diabetes? Diabetologia 62(8):1319–1328.  https://doi.org/10.1007/s00125-019-4928-8 CrossRefGoogle Scholar
  2. 2.
    Kernan WN, Viscoli CM, Furie KL et al (2016) Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med 374(14):1321–1331.  https://doi.org/10.1056/NEJMoa1506930 CrossRefGoogle Scholar
  3. 3.
    DeFronzo RA, Tripathy D, Schwenke DC et al (2011) Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 364(12):1104–1115.  https://doi.org/10.1056/NEJMoa1010949 CrossRefGoogle Scholar
  4. 4.
    Yaghi S, Furie KL, Viscoli CM et al (2018) Pioglitazone prevents stroke in patients with a recent TIA or ischemic stroke: a planned secondary analysis of the IRIS trial. Circulation 137(5):455–463.  https://doi.org/10.1161/CIRCULATIONAHA.117.030458 CrossRefGoogle Scholar
  5. 5.
    Young LH, Viscoli CM, Curtis JP et al (2017) Effects of pioglitazone in patients with insulin resistant without diabetes mellitus. Circulation 135(20):1882–1893.  https://doi.org/10.1161/CIRCULATIONAHA.116.024863 CrossRefGoogle Scholar
  6. 6.
    Inzucchi SE, Viscoli CM, Young LH et al (2016) Pioglitazone prevents diabetes in insulin-resistant patients with cerebrovascular disease. Diabetes Care 39(10):1684–1692.  https://doi.org/10.2337/dc16-0798 CrossRefGoogle Scholar
  7. 7.
    Spence JD, Viscoli CM, Inzucchi SE et al (2019) Pioglitazone for prevention of cardiovascular events in patients with stroke and pre-diabetes: implications for real-world practice. JAMA Neurol 76(5):526–535.  https://doi.org/10.1001/jamaneurol.2019.0079 CrossRefGoogle Scholar
  8. 8.
    Chiasson JL, Josse RG, Gomis R et al (2003) Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. The STOP-NIDDM trial. JAMA 290(4):486–494.  https://doi.org/10.1001/jama.290.4.486 CrossRefGoogle Scholar
  9. 9.
    Holman RR, Coleman RL, Chan JCN et al (2017) Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 5(11):877–886.  https://doi.org/10.1016/S2213-8587(17)30309-1 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Silvio E. Inzucchi
    • 1
    Email author
  • Catherine M. Viscoli
    • 2
  • Lawrence H. Young
    • 3
  • Walter N. Kernan
    • 2
  1. 1.Section of Endocrinology/Fitkin 106Yale School of MedicineNew HavenUSA
  2. 2.Section of General MedicineYale School of MedicineNew HavenUSA
  3. 3.Section of Cardiovascular MedicineYale School of MedicineNew HavenUSA

Personalised recommendations